TrialJournal of clinical oncology : official journal of the American Society of Clinical Oncology2017

Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial.

Toni K Choueiri et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.